FTRE logo

Fortrea Holdings Inc. Stock Price

NasdaqGS:FTRE Community·US$1.3b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 9 Fair Values set on narratives written by author

FTRE Share Price Performance

US$13.66
9.21 (206.97%)
US$16.00
Fair Value
US$13.66
9.21 (206.97%)
14.6% undervalued intrinsic discount
US$16.00
Fair Value
Price US$13.66
AnalystHighTarget US$16.00
AnalystConsensusTarget US$14.44
AnalystLowTarget US$9.50

FTRE Community Narratives

·
Fair Value US$16 14.6% undervalued intrinsic discount

Global Aging And Digital Trends Will Reshape Clinical Research

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
·
Fair Value US$14.44 5.4% undervalued intrinsic discount

FTRE: Stabilizing Healthcare Trends Will Support Resilience Amid Mixed Market Signals

0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
·
Fair Value US$9.5 43.8% overvalued intrinsic discount

Regulation And Pricing Will Erode Margins But May Improve Efficiency

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$9.5
43.8% overvalued intrinsic discount
Profit Margin
16.37%
Future PE
3.02x
Price in 2029
US$12.42
US$16
14.6% undervalued intrinsic discount
Profit Margin
15.46%
Future PE
4.99x
Price in 2029
US$21.55

Trending Discussion

Updated Narratives

FTRE logo

FTRE: Execution Risk Around 2026 Revenue Guidance Will Cap Future Upside

Fair Value: US$9.5 43.8% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
FTRE logo

FTRE: Conservative 2026 Guidance And AI Tools May Support Re Rating

Fair Value: US$16 14.6% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
FTRE logo

FTRE: Margin Recovery And 2026 Guidance Under New Leadership Will Drive Upside

Fair Value: US$14.44 5.4% undervalued intrinsic discount
6 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with imperfect balance sheet.

1 Risk
2 Rewards

Fortrea Holdings Inc. Key Details

US$2.7b

Revenue

US$2.2b

Cost of Revenue

US$510.9m

Gross Profit

US$957.8m

Other Expenses

-US$446.9m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-4.72
18.86%
-16.50%
200.4%
View Full Analysis

About FTRE

Founded
2023
Employees
14000
CEO
Anshul Thakral
WebsiteView website
www.fortrea.com

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Recent FTRE News & Updates

Narrative Update May 07

FTRE: Execution Risk Around 2026 Revenue Guidance Will Cap Future Upside

Analysts have raised their price targets on Fortrea by $3 to $5, and the fair value estimate in this model has shifted from $5.0 to $9.5 as analysts point to moderating discount rate assumptions, slightly positive revenue growth, and higher expected profit margins reflected in a higher forward P/E multiple. Analyst Commentary Recent research on Fortrea shows a split view, with some firms raising price targets by US$3 to US$5, while others have taken a more cautious stance, trimming targets and questioning how much upside is already reflected in the valuation.

Recent updates

No updates